Blue test tubes arranged in a line, disappearing into the background

Drug news

CHMP recommends Forxiga (AstraZeneca/BMS) for Type 2 Diabetes

Read time: 1 mins

Last updated: 19th Apr 2012

Published: 19th Apr 2012

Source: Pharmawand

AstraZeneca and Bristol-Myers Squibb Company announced that the CHMP of the European Medicines Agency has recommended the approval of Forxiga (dapagliflozin) tablets for the treatment of Type 2 Diabetes, as an adjunct to diet and exercise, in combination with other glucose-lowering medicinal products including insulin, and as a monotherapy in metformin intolerant patients.

Learning Zone

Weight Management in Type 2 Diabetes

Explore the comorbidity risk of type 2 diabetes (T2D) and obesity, and the current management options available for T2D and weight loss

Learning Zone Homepage

Cardiovascular Metabolism Learning Zone

The cardiovascular metabolism (CVM) Learning Zone hosted on Medthority.com features over 70 expert opinion videos covering type 2 diabetes and hypertension.

How do you prefer to access medical updates and information?

Listen to a podcast

Watch a video

Read an article

Other

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Moderna reports H5 Flu data

Moderna’s H5 flu vaccine shows strong immune response in Phase 1/2; HHS ends late-stage funding, new paths explored.

Drug news

Cibotercept in PAH ends

Published: 30th May 2025

Drug news

Khindivi cleared for pediatrics

Published: 30th May 2025

See all news